[go: up one dir, main page]

ZA200109868B - Levodopa/carbidopa/entacapone pharmaceutical preparation. - Google Patents

Levodopa/carbidopa/entacapone pharmaceutical preparation.

Info

Publication number
ZA200109868B
ZA200109868B ZA200109868A ZA200109868A ZA200109868B ZA 200109868 B ZA200109868 B ZA 200109868B ZA 200109868 A ZA200109868 A ZA 200109868A ZA 200109868 A ZA200109868 A ZA 200109868A ZA 200109868 B ZA200109868 B ZA 200109868B
Authority
ZA
South Africa
Prior art keywords
carbidopa
levodopa
pharmaceutical preparation
entacapone
entacapone pharmaceutical
Prior art date
Application number
ZA200109868A
Other languages
English (en)
Inventor
Sari Kallioinen
Marja Laaksonen
Mervi Niskanen
Marja Ritala
Matti Virkki
Lasse Kervinen
Jarmo Lintulaakso
Marja Partanen
Kari Vahervuo
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8554988&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200109868(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Publication of ZA200109868B publication Critical patent/ZA200109868B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
ZA200109868A 1999-06-30 2001-11-29 Levodopa/carbidopa/entacapone pharmaceutical preparation. ZA200109868B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI991485A FI109453B (fi) 1999-06-30 1999-06-30 Farmaseuttinen koostumus

Publications (1)

Publication Number Publication Date
ZA200109868B true ZA200109868B (en) 2003-05-28

Family

ID=8554988

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200109868A ZA200109868B (en) 1999-06-30 2001-11-29 Levodopa/carbidopa/entacapone pharmaceutical preparation.

Country Status (42)

Country Link
US (2) US6500867B1 (fr)
EP (1) EP1189608B1 (fr)
JP (2) JP4204783B2 (fr)
KR (1) KR100905428B1 (fr)
CN (1) CN1168440C (fr)
AR (1) AR033796A1 (fr)
AT (1) ATE245417T1 (fr)
AU (1) AU765932B2 (fr)
BG (1) BG65364B1 (fr)
BR (2) BRPI0011867B8 (fr)
CA (1) CA2378469C (fr)
CO (1) CO5180579A1 (fr)
CZ (2) CZ304416B6 (fr)
DE (1) DE60004052T2 (fr)
DK (1) DK1189608T3 (fr)
EA (1) EA004503B1 (fr)
EE (1) EE05473B1 (fr)
ES (1) ES2203495T3 (fr)
FI (1) FI109453B (fr)
FR (1) FR2797587A1 (fr)
GE (1) GEP20043314B (fr)
HK (1) HK1047040B (fr)
HR (1) HRP20020088B1 (fr)
HU (1) HU230395B1 (fr)
IL (1) IL146807A (fr)
IT (1) ITMI20001450A1 (fr)
ME (1) ME00520B (fr)
MX (1) MXPA01013167A (fr)
MY (1) MY127685A (fr)
NO (2) NO330260B1 (fr)
NZ (1) NZ515780A (fr)
PE (1) PE20010399A1 (fr)
PL (1) PL197818B1 (fr)
PT (1) PT1189608E (fr)
RS (1) RS50368B (fr)
SI (1) SI1189608T1 (fr)
SK (1) SK286451B6 (fr)
TR (1) TR200103763T2 (fr)
TW (1) TWI241187B (fr)
UA (1) UA75047C2 (fr)
WO (1) WO2001001984A1 (fr)
ZA (1) ZA200109868B (fr)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
US20030224045A1 (en) * 2002-05-29 2003-12-04 Chien-Hsuan Han Combination immediate release sustained release levodopa/carbidopa dosage forms
US20060013875A1 (en) * 2002-05-29 2006-01-19 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
US20050147670A1 (en) * 2002-05-29 2005-07-07 Impax Laboratories Inc. Oral disintegrating dosage forms
US7094427B2 (en) * 2002-05-29 2006-08-22 Impax Laboratories, Inc. Combination immediate release controlled release levodopa/carbidopa dosage forms
US20040006072A1 (en) * 2002-06-25 2004-01-08 Franz Robert M. Sustained-release alprazolam composition
JP2006506362A (ja) * 2002-10-11 2006-02-23 デポメド・ディベロップメント・リミテッド 胃内保持型レボドパデリバリー形態
AR044007A1 (es) 2003-04-11 2005-08-24 Newron Pharmaceuticals Inc Metodos para el tratamiento de la enfermedad de parkinson
EP1588704A1 (fr) 2004-04-22 2005-10-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamides utiles dans le traitement de l'acroparesthésie nocturne et des troubles de toxicomanie
SE0401842D0 (sv) 2004-07-12 2004-07-12 Dizlin Medical Design Ab Infusion and injection solution of levodopa
WO2006037061A2 (fr) * 2004-09-28 2006-04-06 Farouk Karoum Compositions et procedes d'utilisation de d-dopa pour traiter la maladie de parkinson
JP2008519811A (ja) 2004-11-10 2008-06-12 オリオン コーポレーション 下肢静止不能症候群の治療
EA013161B1 (ru) * 2005-06-08 2010-02-26 Орион Корпорейшн Дозированная форма для перорального применения
AU2012216377C1 (en) * 2005-06-08 2013-10-10 Orion Corporation Oral dosage form
US20080299204A1 (en) * 2005-06-23 2008-12-04 Spherics, Inc. Dosage forms for movement disorder treatment
MY148644A (en) 2005-07-18 2013-05-15 Orion Corp New pharmaceutical compounds
PL1907382T3 (pl) 2005-07-26 2016-01-29 Bial Portela & Ca Sa Pochodne nitrokatecholowe jako inhibitory COMT
US8877802B2 (en) * 2005-07-28 2014-11-04 Duke Univerity Antiparkinsonian action of phenylisopropylamines
WO2007034024A2 (fr) * 2005-09-21 2007-03-29 Orion Corporation Traitement de symptomes de troubles moteurs
WO2007056570A2 (fr) * 2005-11-07 2007-05-18 Teva Pharmaceutical Industries Ltd. Compositions de levodopa
WO2007069274A2 (fr) * 2005-11-09 2007-06-21 Torrent Pharmaceuticals Limited Composition pharmaceutique
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
CN100384411C (zh) * 2006-03-17 2008-04-30 北京科信必成医药科技发展有限公司 卡左双多巴口腔崩解片
WO2007113371A1 (fr) * 2006-03-31 2007-10-11 Iprbox Oy Préparation pharmaceutique et méthode d'élaboration de ladite préparation
EP1845097A1 (fr) 2006-04-10 2007-10-17 Portela & Ca., S.A. Derives de oxadiazole en tant qu' inhibiteurs de l'enzyme COMT
EP1870097A1 (fr) * 2006-06-15 2007-12-26 Newron Pharmaceuticals S.p.A. Dérivés d'alpha-aminoamide pour le traitement de troubles cognitifs
US8106056B2 (en) * 2006-06-16 2012-01-31 Solvay Pharmaceuticals B.V. Combination preparations comprising bifeprunox and a dopamine agonist
US20080131492A1 (en) * 2006-06-23 2008-06-05 Spherics, Inc. Dosage forms for movement disorder treatment
WO2008053297A2 (fr) * 2006-10-30 2008-05-08 Wockhardt Research Centre Compositions pharmaceutiques comprenant l'entacapone, la lévodopa, et la carbidopa
US20100316712A1 (en) * 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
US20100104634A1 (en) * 2006-12-27 2010-04-29 Mahesh Rameshwar Kalantri Pharmaceutical compositions of entacapone
EP1946756A1 (fr) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Utilisation d'entacapone dans les compositions cosmétiques, dermatologiques et pharmaceutiques
CA2678391C (fr) 2007-01-31 2017-01-17 David Alexander Learmonth Schema posologique pour des inhibiteurs de la catechol-o-methyltransferase
US20110171275A1 (en) * 2007-08-20 2011-07-14 Team Academy Of Pharmaceutical Science Gastroretentive drug delivery system, preparation method and use thereof
AU2009211028B2 (en) * 2008-02-06 2013-12-05 Wockhardt Research Centre Pharmaceutical compositions of entacapone, levodopa and carbidopa with improved bioavailability
BRPI0907727A2 (pt) * 2008-02-06 2017-06-13 Wockhardt Res Centre composições farmacêuticas de entacapone co-micronizado com alcoóis de açúcar
RU2010139315A (ru) 2008-03-17 2012-04-27 Биал - Портела Энд Ка., С.А. (Pt) Кристаллические формы 5-[3-(2,5-дихлор-4,6-диметил-1-окси-пиридин-3-ил)[1,2,4]оксадиазол-5-ил]-3-нитробензол-1,2-диола
BRPI0918408A2 (pt) * 2008-08-22 2015-11-24 Wockhardt Research Center composição farmacêutica de dose oral unitária simples compreendendo levodopa, carbidopa e entacapona ou sais das mesmas
US9289392B2 (en) * 2008-08-22 2016-03-22 Wockhardt Ltd. Extended release pharmaceutical composition of entacapone or salts thereof
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
EP2233131A1 (fr) 2009-03-23 2010-09-29 Laboratorios Lesvi, S.L. Composition pharmaceutique contenant de la lévodopa, un inhibiteur de la catéchol-O-méthyl-transférase et de la carbidopa
RU2701731C2 (ru) 2009-04-01 2019-10-01 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
EP3777839A1 (fr) * 2009-05-19 2021-02-17 Neuroderm Ltd Compositions pour administration continue d'inhibiteurs de la dopa décarboxylase
US9750702B2 (en) 2009-12-25 2017-09-05 Innopharmax, Inc. Pharmaceutical composition for treating parkinson's disease and preparation method thereof
JP5774610B2 (ja) 2010-03-04 2015-09-09 オリオン コーポレーション パーキンソン病の治療方法
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
NZ610911A (en) * 2010-11-15 2015-02-27 Neuroderm Ltd Continuous administration of l-dopa, dopa decarboxylase inhibitors, catechol-o-methyl transferase inhibitors and compositions for same
US20140045900A1 (en) * 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
EP2508174A1 (fr) 2011-04-06 2012-10-10 Ljiljana Sovic Brkicic Composition pharmaceutique
WO2012147099A1 (fr) * 2011-04-25 2012-11-01 Suven Nishtaa Pharma Pvt. Ltd. Compositions pharmaceutiques de lévodopa, de carbidopa et d'entacapone
JP5855230B2 (ja) * 2011-04-26 2016-02-09 イノファーマックス インコーポレイテッド エンタカポン組成物
EP3604299B1 (fr) 2011-12-13 2023-07-26 Bial-Portela & CA, S.A. Composé chimique utile en tant qu'intermédiaire pour la préparation d'un inhibiteur de transférase catéchol-0-méthyle
TR201204839A2 (tr) 2012-04-25 2012-12-21 Ali̇ Rai̇f İlaç Sanayi̇ A.Ş. Uzatılmış salım sağlayan levodopa karbıdopa entakapon içeren tablet formülasyonu.
EP2854764B1 (fr) 2012-06-05 2018-12-12 Neuroderm Ltd Compositions comprenant de l'apomorphine et des acides organiques, et leurs utilisations
US20160022573A1 (en) * 2013-03-13 2016-01-28 Neuroderm, Ltd. Method for treatment of parkinson's disease
EP2799065A1 (fr) * 2013-04-30 2014-11-05 Deva Holding Anonim Sirketi Lévodopa carbidopa entacapone formulations pharmaceutiques
CA2926082C (fr) 2013-10-07 2022-06-14 Impax Laboratories, Inc. Formulations mucoadhesives a liberation controlee de levodopa et/ou d'esters de levodopa et leurs utilisations
US10987313B2 (en) 2013-10-07 2021-04-27 Impax Laboratories, Llc Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
EP3777833B1 (fr) 2014-03-13 2023-10-18 Neuroderm Ltd. Compositions d'inhibiteurs de dopa-décarboxylase
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
CN107072973A (zh) 2014-09-04 2017-08-18 劳波索尔制药有限公司 含左旋多巴、多巴胺脱羧酶抑制剂和comt抑制剂的药物组合物及其施用方法
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ，エス．アー． パーキンソン病を遅延させるための医薬
EP3236957A1 (fr) 2014-12-23 2017-11-01 Pharmathen S.A. Préparation pharmaceutique de lévodopa/carbidopa/entacapone et son procédé de préparation
US10555922B2 (en) 2015-09-04 2020-02-11 Lobsor Pharmaceuticals Aktiebolag Method of treating a dopamine related disorder in a subject by administering levodopa, in combination with a dopamine decarboxylase inhibitor and a catechol-o-methyltransferase inhibitor
JP7227896B2 (ja) * 2016-07-11 2023-02-22 コンテラ ファーマ エー／エス 朝の無動状態を治療するための拍動性薬物送達系
WO2018034626A1 (fr) 2016-08-18 2018-02-22 İlko İlaç Sanayi Ve Ticaret Anonim Şirketi Formulation de comprimé antiparkinsonien à profil de dissolution amélioré
WO2019145773A1 (fr) 2017-12-15 2019-08-01 Nos Life Sciences Corporation Formulations encapsulées dans des liposomes
AU2019237857B2 (en) 2018-03-23 2024-11-21 Lobsor Pharmaceuticals Aktiebolag Continuous administration of pharmaceutical composition for treatment of neurodegenerative disorders
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
WO2022140448A1 (fr) 2020-12-22 2022-06-30 Amneal Pharmaceuticals Llc Schéma posologique de lévodopa
US11986449B2 (en) 2020-12-22 2024-05-21 Amneal Pharmaceuticals Llc Levodopa dosing regimen
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
GB8521350D0 (en) * 1985-08-28 1985-10-02 Euro Celtique Sa Analgesic composition
US5236952A (en) 1986-03-11 1993-08-17 Hoffmann-La Roche Inc. Catechol derivatives
NZ220599A (en) * 1986-06-16 1990-10-26 Merck & Co Inc Controlled release oral dosage formulation of carbidopa and levodopa
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
DE4101873C2 (de) * 1991-01-23 1993-12-09 Isis Pharma Gmbh Peroral applizierbare Arzneiform zur Behandlung zentraler Dopaminmangelzustände
US5888534A (en) 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB2321190B (en) * 1997-01-16 2000-09-20 Britannia Pharmaceuticals Ltd Pharmaceutical composition
US6599530B2 (en) 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
FI109453B (fi) 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus

Also Published As

Publication number Publication date
HK1047040A1 (en) 2003-02-07
FI109453B (fi) 2002-08-15
NO20110090L (no) 2002-02-25
EA004503B1 (ru) 2004-04-29
BR0011867A (pt) 2002-03-05
NO330260B1 (no) 2011-03-14
TWI241187B (en) 2005-10-11
EA200200106A1 (ru) 2002-06-27
BRPI0011867B8 (pt) 2021-05-25
PT1189608E (pt) 2003-12-31
DK1189608T3 (da) 2003-11-10
SK19232001A3 (sk) 2002-06-04
HRP20020088A2 (en) 2005-10-31
NO20016203L (no) 2002-02-25
PL352775A1 (en) 2003-09-08
FI991485L (fi) 2000-12-31
PL197818B1 (pl) 2008-04-30
WO2001001984A1 (fr) 2001-01-11
ITMI20001450A1 (it) 2001-12-28
JP4885896B2 (ja) 2012-02-29
MY127685A (en) 2006-12-29
CN1358090A (zh) 2002-07-10
CO5180579A1 (es) 2002-07-30
HUP0202273A2 (en) 2002-10-28
FI991485A0 (fi) 1999-06-30
UA75047C2 (en) 2006-03-15
PE20010399A1 (es) 2001-04-10
US6500867B1 (en) 2002-12-31
CZ304416B6 (cs) 2014-04-23
FR2797587A1 (fr) 2001-02-23
CN1168440C (zh) 2004-09-29
JP2008156373A (ja) 2008-07-10
ATE245417T1 (de) 2003-08-15
BG65364B1 (bg) 2008-04-30
NZ515780A (en) 2004-06-25
KR100905428B1 (ko) 2009-06-30
HU230395B1 (hu) 2016-04-28
SK286451B6 (sk) 2008-10-07
TR200103763T2 (tr) 2002-04-22
BG106251A (en) 2002-08-30
HK1047040B (zh) 2005-04-29
RS50368B (sr) 2009-11-10
NO20016203D0 (no) 2001-12-18
YU92501A (sh) 2004-09-03
MXPA01013167A (es) 2002-07-02
HUP0202273A3 (en) 2002-11-28
EE200100716A (et) 2003-02-17
CZ20014636A3 (cs) 2002-05-15
IL146807A (en) 2006-10-05
AU765932B2 (en) 2003-10-02
AU5830600A (en) 2001-01-22
KR20020010155A (ko) 2002-02-02
US6797732B2 (en) 2004-09-28
EP1189608A1 (fr) 2002-03-27
CA2378469C (fr) 2009-10-06
ES2203495T3 (es) 2004-04-16
DE60004052T2 (de) 2004-04-15
ME00520B (me) 2011-10-10
DE60004052D1 (de) 2003-08-28
EE05473B1 (et) 2011-10-17
ITMI20001450A0 (it) 2000-06-28
US20030017201A1 (en) 2003-01-23
BRPI0011867B1 (pt) 2019-01-08
JP2003503454A (ja) 2003-01-28
CA2378469A1 (fr) 2001-01-11
SI1189608T1 (en) 2004-04-30
CZ303010B6 (cs) 2012-02-29
GEP20043314B (en) 2004-02-10
HRP20020088B1 (hr) 2007-05-31
JP4204783B2 (ja) 2009-01-07
AR033796A1 (es) 2004-01-07
EP1189608B1 (fr) 2003-07-23

Similar Documents

Publication Publication Date Title
ZA200109868B (en) Levodopa/carbidopa/entacapone pharmaceutical preparation.
ZA993338B (en) Pharmaceutical formulations.
ZA9811959B (en) Ibuprofen composition.
ZA991307B (en) Antibodies against human CD40.
ZA200105453B (en) Potentiation of Anti-CD38-immunotoxin cytotoxicity.
MXPA01010676A (es) Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide.
ZA200204127B (en) New aminopropylphosphinic acids.
ZA200108304B (en) Agrochemical formulations.
ZA982356B (en) Food fortification.
ZA200104280B (en) Pharmaceutical combination preparations.
SI1112065T1 (en) Pharmaceutical composition comprising entacapone or nitecapone as well as a cross-linked cellulose deivative
ZA200201057B (en) Radiopharmaceutical products and their preparation procedure.
ZA200005510B (en) Pharmaceutical composition.
ZA200203707B (en) Pharmaceutical combinations.
ZA200000857B (en) Pharmaceutical composition.
PL344834A1 (en) Pharmaceutical levothyroxine preparation
ZA991212B (en) Pharmaceutical combinations comprising tramadol.
HU229988B1 (en) Aqueous lysine solution
ZA200204460B (en) Valnemulin formulation.
ZA982346B (en) Food rheology improvements.
MXPA00007601A (es) Cronometro.
AU4106000A (en) Ibuprofen solution
ZA200110454B (en) Pharmaceutical complex.
ZA200102900B (en) Sertraline Oral concentrate.
ZA994697B (en) Pharmaceutical formulation.